Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.21B, +9.9% YoY · Filed Nov 2, 2026
Idexx Laboratories Inc /DE (IDXX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.2 billion and net income of $317.1 million. Free cash flow was $420.8 million. As of Sep 30, 2026 it held $197.5 million in cash and investments and $499.0 million in total debt.
Revenue
$1.21B
+9.9% vs year-ago quarter
Net income
$317.14M
+15.5% vs year-ago quarter
Operating cash flow
$449.72M
+11.8% vs year-ago quarter
Free cash flow
$420.79M
+13.4% vs year-ago quarter
EPS
$4.01
+17.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
78.79M
-1.3% vs year-ago quarter
Net cash
$-301.43M
Q3 FY2026
Operating margin
32.3%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IDXX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westbrook, ME
- SEC filer status
- Large accelerated filer
- SEC CIK
- 874716
Other In Vitro & In Vivo Diagnostic Substances companies
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.1B | $1.1B |
| Operating income | $402.3M | $425.6M | $362.6M | $315.6M | $354.8M |
| Net income | $317.1M | $338.4M | $278.4M | $248.2M | $274.6M |
| Diluted EPS | $4.01 | $4.27 | $3.47 | $3.08 | $3.40 |
| Operating cash flow | $449.7M | $347.2M | $266.2M | $355.8M | $402.3M |
| Free cash flow | $420.8M | $322.5M | $234.3M | $326.3M | $371.2M |
| Total assets | $3.7B | $3.4B | $3.4B | $3.4B | $3.4B |
| Total liabilities | $1.8B | $1.8B | $1.8B | $1.7B | $1.8B |
| Stockholders' equity | $1.9B | $1.6B | $1.6B | $1.6B | $1.6B |
| Cash and investments | $197.5M | $196.9M | $200.5M | $180.1M | $208.2M |
| Total debt | $499.0M | $577.1M | $575.5M | $578.2M | $658.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 15, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 1005 Idexx Laboratories Inc /DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.